Amneal Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held by Amneal Pharmaceuticals, Inc. on May 9, 2022. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
All three proposals submitted to stockholders were approved. The specific voting results were as follows:
- Proposal 1 (Director Elections): All 10 director nominees were elected. Notable vote counts included Chintu Patel (236,380,089 For) and J. Kevin Buchi (200,540,414 For). There were 20,029,960 broker non-votes for each nominee.
- Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 236,202,110 votes For, 1,193,006 Against, and 270,959 Abstain.
- Proposal 3 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 256,967,689 votes For, 253,537 Against, and 474,809 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the election of the 10 nominees.
- Confirm the tenure of the newly elected directors, which extends until the 2023 Annual Meeting.
- Note the significant number of broker non-votes (20,029,960) recorded for the director elections.
- Review the full proxy statement for details on the specific compensation packages approved under Proposal 2.